Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Blood Processing, Blood Pumps, Diagnostics, Hemorrhage, Bleeding, Hemostatis, Transfusion, Intravenous (IV) Management
Aethlon Medical, Inc. (NASDAQ: AEMD)

Organization & Developments: Aethlon

Parents

2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
2011: DARPA Awards Aethlon $6.8M for Technology to Combat Sepsis (2011)
2022: Aethlon Medical (AEMD) Investor Presentation - Slideshow_seekingalpha.com
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
As a therapeutic device, the Hemopurifier® provides a pipeline into four significant market opportunities: 1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from ci
Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.